Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Sponsor: Perceive Biotherapeutics, Inc.
Summary
This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.
Official title: Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2022-11-17
Completion Date
2025-11
Last Updated
2024-04-11
Healthy Volunteers
No
Interventions
VOY-101
Intravitreal injection of VOY-101
Locations (3)
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Retina Consultants of Texas
Bellaire, Texas, United States
University of Utah
Salt Lake City, Utah, United States